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http://www.biomedcentral.com/1471-2407/13/476RESEARCH ARTICLE Open AccessChemotherapy-induced hyaluronan production:
a novel chemoresistance mechanism in ovarian
cancer
Carmela Ricciardelli1*†, Miranda P Ween1,2†, Noor A Lokman1, Izza A Tan1, Carmen E Pyragius1
and Martin K Oehler1,3Abstract
Background: Hyaluronan (HA) an important component of the extracellular matrix, has been linked to tumor
progression and drug resistance in several malignancies. However, limited data is available for ovarian cancer. This
study investigated the role of hyaluronan (HA) and a potential link between the HA-CD44 pathway and membrane
ATP binding cassette (ABC) transporter proteins in ovarian cancer chemoresistance.
Methods: We investigated the ability of HA to block the cytotoxic effects of the chemotherapy drug carboplatin,
and to regulate the expression of ABC transporters in ovarian cancer cells. We also examined HA serum levels in
ovarian cancer patients prior to and following chemotherapy and assessed its prognostic relevance.
Results: HA increased the survival of carboplatin treated ovarian cancer cells expressing the HA receptor, CD44
(OVCAR-5 and OV-90). Carboplatin significantly increased expression of HAS2, HAS3 and ABCC2 and HA secretion in
ovarian cancer cell conditioned media. Serum HA levels were significantly increased in patients following platinum
based chemotherapy and at both 1st and 2nd recurrence when compared with HA levels prior to treatment. High
serum HA levels (>50 μg/ml) prior to chemotherapy treatment were associated with significantly reduced
progression-free (P = 0.014) and overall survival (P = 0.036). HA production in ovarian cancer cells was increased in
cancer tissues collected following chemotherapy treatment and at recurrence. Furthermore HA treatment
significantly increased the expression of ABC drug transporters (ABCB3, ABCC1, ABCC2, and ABCC3), but only in
ovarian cancer cells expressing CD44. The effects of HA and carboplatin on ABC transporter expression in ovarian
cancer cells could be abrogated by HA oligomer treatment. Importantly, HA oligomers increased the sensitivity of
chemoresistant SKOV3 cells to carboplatin.
Conclusions: Our findings indicate that carboplatin chemotherapy induces HA production which can contribute to
chemoresistance by regulating ABC transporter expression. The HA-CD44 signaling pathway is therefore a
promising target in platinum resistant ovarian cancer.
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Ovarian cancer is the most lethal gynecological cancer
and ranks as the fourth most common cause of cancer-
related death in women in the Western world [1]. The
standard treatment for advanced ovarian cancer is
debulking surgery, followed by platinum-based chemo-
therapy. This standard treatment results in a complete
response rate of 40-60%, however, more than 90% of
these patients relapse after 2 years [2]. Recurrent ovarian
cancer in most cases becomes incurable due to the de-
velopment of chemoresistance.
Chemoresistance is multifactorial in nature involving
tumor-related and drug-related factors, as well as inter-
actions with the tumor microenvironment itself. A well
established cause involves increased expression of mem-
bers of the membrane efflux ATP binding cassette
(ABC) transporter family, which decrease the intracellu-
lar accumulation and retention of chemotherapy drugs
[3]. ABC transporters are a family of membrane pro-
teins that transport a wide range of substrates, including
metabolic products, nutrients, lipids, and drugs, across
extracellular and intracellular membranes, and have
been shown to play an important role in many human
diseases [4,5]. Phylogenetic analysis places the 48 known
human ABC transporters into 7 distinct subfamilies
(ABCA-ABCG) [4]. The first ABC transporter identified
was MDR1 (ABCB1), also known as p-glycoprotein [6].
ABCB1 plays a critical role in drug fluxes and chemo-
resistance in many malignancies, including ovarian cancer
[7-10]. Other ABC transporters, including ABCB3 (TAP2),
ABCC1 (MRP1), ABCC2 (MRP2, cMOAT), and ABCC3
(MRP3), have been shown to be involved in ovarian cancer
chemoresistance [11-15].
A component of the tumor microenvironment linked
to chemoresistance is the extracellular matrix (ECM)
molecule, hyaluronan (HA) [16]. HA is a large polysac-
charide that is assembled into pericellular and ECM in
many tissues [17]. HA has a role in various cell functions
such as adhesion, motility, and differentiation. It has also
been implicated to be a key player in cancer metastasis
[17,18]. Many human tumors, including ovarian cancer,
are surrounded by a connective tissue matrix enriched
with HA [18-20]. Increased HA has been shown to be
an independent predictor of ovarian cancer survival [19].
HA levels significantly correlate with the degree of inva-
siveness and metastatic potential in malignant ovarian
tumors [19,21], and it promotes the attachment of can-
cer cells to peritoneal cells via interactions with its major
surface receptor, CD44 [22-25].
HA has been shown to reduce the ability of chemo-
therapy drugs to cause cancer cell death in a variety of
malignancies [26-29]. Furthermore, several studies have
demonstrated that HA interactions with CD44 can in-
crease resistance to numerous chemotherapy drugs andincrease the expression of the ABC drug transporters
[28,30-34]. The co-localization of CD44 with ABCB1
and ABCC2 in ovarian cancer tissues suggests a functional
link between CD44 expression and chemoresistance [35].
However, knowledge regarding the importance of HA-
CD44 interactions in mediating chemoresistance and
regulating ABC transporter expression in ovarian cancer
is limited. In this study we therefore assessed the ability of
HA to block the cytotoxic effects of the chemotherapy
drug carboplatin (CBP) on ovarian cancer cells and inves-
tigated a potential link between the HA-CD44 pathway
and ABC transporter expression. To relate findings with
the clinical situation, we measured HA serum levels in
ovarian cancer patients at diagnosis, during chemotherapy




The human ovarian cancer cell lines OVCAR-3, SKOV-3,
and OV-90 were obtained from American Type Culture
Collection (ATCC, Manassas, VA, USA). OVCAR-5 cells
were obtained from Dr. Thomas Hamilton (Fox Chase
Cancer Center, Philadelphia, PA) [36]. All ovarian can-
cer cell lines were maintained in RPMI 1640 medium
supplemented with 4 mM L-glutamine and antibiotics
(100 U penicillin G, 100 μg/ml streptomycin sulfate and
0.25 μg/ml amphotericin B, Sigma Aldrich, St Louis,
MO, USA) at 37°C in an environment of 5% CO2 as
described previously [37].
Cell survival assays
Cells were plated at 5,000 cells per well, grown for 24 hr,
and then treated with CBP (0–300 μM, Mayne Pharma,
Victoria, Australia) for 72 hr in normal growth media.
Cell survival was calculated by MTT assay, as per the
manufacturer’s instructions (Sigma Aldrich). The inhibi-
tory concentration (LD50) of CBP was calculated from
three independent experiments performed in triplicate
using exponential regression curve fitting. To assess the
effect of HA on cell survival, cells were plated at 5,000
cells per well, grown for 24 hr, and then treated with
IC50 dose of CBP and HA (0–100 μg/ml, H1504, Sigma
Aldrich) ± CD44 neutralizing antibody (Clone A020,
20 μg/ml Calbiochem, NSW, Australia), control IgG
(20 μg/ml, BD Biosciences, North Ryde, NSW, Australia)
or HA oligomers (HYA-OLIGO 6–10, 10–250 μg/ml,
North Star Bioproducts, Associates of Cape Cod Inc,
East Falmouth, MA, USA or 10-250 μg/ml HYA-OLIGO
8, Hyalose LLC, Oklahoma City, OK, USA) for 72 hr be-
fore cell survival assessment by MTT assay. Chemosen-
sitivity of SKOV-3 cells to CBP in presence of HA
oligomers (250 μg/ml) was determined using the MTT
assay as described above. Exponential curve fitting was
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LD50 in the presence of CBP alone and combined with
HA oligomers.
Quantitative real-time PCR
Cells were plated at 5,000 cells per well for 24 hr, and then
treated with control medium, CBP LD50 dose or HA
(5 μg/ml) for 72 hr. Cells were also treated CBP or HA in
the presence or absence of HA oligomers (10-250 μg/ml
HYA-OLIGO 6-8, Hyalose LLC). Total RNA was isolated
from ovarian cancer cell lines and reverse transcribed
using the TaqMan® Gene expression Cells-to-CT™ kit
(Applied Biosystems, Mulgrave, Victoria, Australia), as
per the manufacturer’s instructions. Briefly, lysis solu-
tion with DNAse was added to each well and incubated
for 5 min at room temperature. Stop solution was then
added to each well and mixed. The lysate (10 μl) was
added to a 40 μl reverse transcription master mix and
reverse transcribed for 1 hr. Resultant cDNA was stored
as 50 μl aliquots at −20°C for qRT-PCR analysis.
qRT-PCR reactions were performed on triplicate sam-
ples using TaqMan® primer sets for genes of interest, as
detailed in Additional file 1: Table S1 using the 7900HT
Fast Real-Time PCR System (Applied Biosystems,
Mulgrave, Victoria, Australia). Briefly, PCR reactions
were made up to 10 μl and contained TaqMan® Gene
Expression Master Mix (2×), primers for the gene of
interest, nuclease free water, and the sample cDNA. PCR
cycling conditions were as follows: 50°C for 2 min, 95°C
for 10 min (with 40 cycles following of 95°C for 15 sec),
and 60°C for 1 min. CT values were normalised to the
house keeping gene β-actin and calibrated to no treat-
ment control using the 2-ΔΔCT method.
HA ELISA assay
An HA ELISA kit (DY3614, R&D Systems, Minneapolis,
MN) was used to determine the concentration of HA in
serum samples or conditioned media (CM), as per manu-
facturer’s instructions. Serum was assessed from ovarian
cancer patients at diagnosis (n = 101), after chemotherapy
(n = 52), at 1st recurrence (n = 17) and 2nd recurrence (n = 5).
Matched serum samples at diagnosis and following at least
two cycles of chemotherapy were available from 32 pa-
tients. Serum samples were also obtained from patients
with benign ovarian tumors (n = 22) and healthy controls
(n = 27). All samples were collected with approval from
the Royal Adelaide Hospital Human Ethics Committee
and informed written consent was obtained from all par-
ticipants involved in this study. CM was collected from
cells (OVCAR-5, OVCAR-3, OV-90, and SKOV-3) plated
at 5,000 cells per well and grown for 24 hr before 72 hr
treatment with their IC50 concentration of CBP or control
media. The detection limit of the assay was 100 pg/ml,
and the coefficient of variation between assays was 9.21%.HA staining in ovarian cancer tissues
Formalin fixed tissue was obtained from ovarian cancer
patients at surgery (n = 10), postchemotherapy (n = 9)
and at recurrence (n = 4). Tissues samples were collected
with approval from the Royal Adelaide Hospital Human
Ethics Committee. Informed written consent was obtained
from all participants involved in this study. Tissue sections
(5 μm) were mounted onto positively charged slides
(SuperFrost VR Plus, Menzel-Glaser, Braunschweig,
Germany) and heated at 60°C for 1.5 hr. HA in ovarian
cancer sections was detected using HABP (2 μg/ml,
Seikagaku Corp, Japan) [38]. The intensity of HA in the
epithelial and stromal compartments was assessed using a
manual scoring method: strong (3+), moderate (2+), weak
(1+), or negative (0). A score of 0 or 1+ was defined as low
HA staining and a score or 2+ or 3+ was defined as high
HA staining. The % of HA positive cancer cells were inde-
pendently assessed in the three tissue groups.
HA staining and ABCC2 immunocytochemistry
OVCAR-5 cells (2×104 cells/well) were plated in 8 well
tissue culture chamber slides (Nunclon™ Lab-Tek II
Chamber slide, RS Glass Slide, Naperville, IL) in 500 μl
10% FBS RPMI for 24 hr and treated for 72 hr with IC50
concentration of CBP or control media. OVCAR-5 cells
were fixed with cold 100% methanol (5 min) and cold
100% acetone (3 min), washed with PBS and blocked
with 5% donkey serum and incubated overnight with
biotinylated HABP (2 μg/ml, Seikagaku Corp, Japan)
and/or mouse ABCC2 monoclonal antibody (1/25, Clone
M2I-4, Abcam, Cambridge, United Kingdom). HA and
ABCC2 were visualized with Cy3-conjugated streptavidin
(1/100, 1 hr at RT, catalogue no: 016-160-084, Jackson
Immunoresearch Laboratories, West Grove, PA, USA) or
FITC-conjugated AffiniPure donkey anti-mouse (1/100, 1 hr
at RT, catalogue no: 715-096-151, Jackson Immunoresearch
Laboratories), respectively. Nuclei were stained with 4′,6′-
diamidino-2-phenylindole dihydrochloride solution (DAPI,
Molecular Probes, Eugene, OR, USA) and slides were
mounted with fluorescent mounting medium (Dako
Labs, Glostrup, Denmark). Cells were viewed with an
epifluorescence microscope (BX50, Olympus Australia)
and imaged using a 20× objective and a Spot RT digital
camera (Diagnostic Instruments, Sterling Heights, MI).
Negative controls included only Cy3-conjugated streptavidin
and FITC-conjugated AffiniPure donkey anti-mouse and
also Streptomyces hyaluronidase (30 min RT, 10 U/ml,
Sigma-Aldrich) treatment for the HA staining.
Statistical analyses
All analyses were performed using the PASW 17.0 Stat-
istical software (SPSS Inc., Chicago, IL). The Mann–
Whitney U, Kruskal-Wallis, Wilcoxon signed rank or
Chi Square tests were used to determine statistical
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ies, the Student’s t-test and one way ANOVA test with
the Tukey or Dunnett C post-hoc tests were used to de-
termine statistical significance between control and
treatment groups. Clinical follow-up data for disease
progression and survival was available for 77 and 83
ovarian cancer patients respectively. All patients re-
ceived either CBP alone or a combination of CBP and
paclitaxel. Forty five percent (35/77) of the patient’s
progressed and 27.7% (23/83) died from ovarian cancer
at the time of census (1st December 2012). Kaplan-
Meier and Cox regression analyses with progression or
death due to ovarian cancer was used as the endpoint to
determine whether HA levels prior to chemotherapy treat-
ment were related to progression-free survival (PFS) or
overall survival (OS). Statistical significance was accepted
at P < 0.05.Figure 1 HA increases ovarian cancer cell resistance to
carboplatin. A. CBP dose response growth curves for ovarian cancer
cell lines. LD50 for SKOV3, OV-90, OVCAR-3 and OVCAR-5 was calculated
using exponential curve fitting. B. Cell survival of ovarian cancer cells
treated with CBP (LD50 dose) ± HA (0–100 μg/ml) after 72 hr. HA
treatment increased the survival of OVCAR-5 and OV-90 cells, but not
of SKOV-3 and OVCAR-3 cells following treatment with CBP (LD50
dose). Data are expressed as percentage of no CBP control, mean ±
SEM from 3–5 independent experiments performed in triplicate.
*, significantly different from control (P < 0.05, independent t test).Results
HA treatment increases ovarian cancer cell resistance to
carboplatin
To determine whether HA contributes to chemoresistance,
we assessed the ability of HA to block the cytotoxic effect
of CBP. We determined the CBP LD50 dose for a range of
ovarian cancer cell lines with increasing invasive capacity.
The SKOV-3 cells were the most resistant to CBP (LD50 =
184 μM), followed by OV-90 (LD50 = 145 μM), OVCAR-3
(LD50 = 113 μM) and OVCAR-5 (LD50 = 81 μM, Figure 1A).
We assessed cell survival following treatment with both
CBP + HA or CBP alone using the LD50 CBP dose deter-
mined for each cell line. HA treatment increasedFigure 2 HA-CD44 interactions mediate chemoresistance in
ovarian cancer cells. A. HA oligomers (HYA oligo, 250 μg/ml) and
anti-rat neutralizing CD44 monoclonal antibody (20 μg/ml) blocked
increased survival of OVCAR-5 and OV-90 cells treated with HA
(5 μg/ml) and carboplatin (CBP, LD50 dose), but had no effect on
OVCAR-3 cells. B. HYA oligo increased the sensitivity of SKOV-3 cells
to CBP. SKOV-3 cells were treated with CBP (0–200 μM) ± HYA oligo
(250 μg/ml) for 72 hr. The CBP LD50 calculated using exponential
curve fitting was 173 μM in the presence of CBP alone and reduced
to 123 μM when CBP was combined with HYA oligo. Data are
expressed as percentage of control, mean ± SD from 2 independent
experiments performed in triplicate. *, significantly different from
control (P < 0.05, independent t test).
Figure 3 Carboplatin treatment increases HA production by
ovarian cancer cells. A. HA levels in the CM of ovarian cancer cell
lines, determined by ELISA assay. Data represent mean ± SEM from 3
independent experiments performed in duplicate. *, significantly
different from no CBP control (P < 0.05, independent t test).
B. qRT-PCR for HAS2 expression. C. qRT-PCR for HAS3 expression.
Relative gene expression in B and C was determined by calibration
against no CBP control and normalized to the house keeping gene
β-actin using the 2-ΔΔCT method. Data represents mean ± SEM from
2 independent experiments performed in triplicate. *, significantly
different from no CBP control (P < 0.05, independent t test).
C = no CBP, CBP = carboplatin (LD50 dose), CM = conditioned media.
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the survival of SKOV-3 or OVCAR-3 cells (Figure 1B).
As little as 0.01 μg/ml HA and 0.05 μg/ml HA were able
to significantly increase survival of OVCAR-5 and OV-
90 cells, respectively. HA treatment alone (0.05-100 μg/ml)
did not affect cell proliferation of any of the ovarian cancer
cell lines however higher concentration of HA (500 μg/ml)
significantly inhibited growth of OVCAR-5 and SKOV3
cells (Additional file 2: Figure S1). The increased cell
survival (OVCAR-5 and OV-90) observed with CBP and
HA treatment was significantly blocked by either the
addition of HA oligomers or a neutralising CD44 anti-
body (Figure 2A). HA oligomers had no effect on the sur-
vival of OVCAR-3 (Figure 2A). Importantly, HA oligomers
significantly increased the sensitivity of chemoresistant
SKOV3 ovarian cancer cells to CBP. Combined treatment
with CBP and HA oligomers, significantly reduced SKOV3
survival and reduced the CBP LD50 from 173 μM to
123 μM (Figure 2B).Chemotherapy treatment increases HA production and
ABCC2 expression by ovarian cancer cells
We investigated whether CBP increases HA production
and the expression of ABCC2, an ABC transporter shown
to confer ovarian cancer cell resistance to platinum based
chemotherapy agents including CBP [13,39]. Treatment
with the LD50 CBP dose significantly increased HA secre-
tion in the CM of OVCAR-5 (3.7 fold), OVCAR-3 (4.1
fold), SKOV-3 cells (1.6 fold), and OV-90 cells (2.6 fold)
(P < 0.05) (Figure 3A). SKOV-3 cells, the most CBP-
resistant cell line, produced the highest levels of HA.
Increased Has2 and Has3 expression was observed in
OVCAR-5 cells treated with CBP (6 and 44 fold, respect-
ively, Figure 3B and 3C). Has3 (Figure 3C), but not Has2
(Figure 3B), expression was increased in OV-90 and
OVCAR-3 cells following treatment with CBP. HA levels
in CM correlated with Has2 and Has3 gene expression
(data not shown).
Treatment with LD50 CBP dose significantly increased
ABCC2 expression in OV90 and OVCAR-5 cells but not
OVCAR-3 cells. The increased ABCC2 expression could
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in OVCAR-5 cells (Figure 4A). Increased HA and ABCC2
production in OVCAR-5 cells after exposure to CBP was
confirmed by immunocytochemistry (Figure 4B). In the ab-
sence of CBP treatment, very little HA and ABCC2 were
produced by OVCAR-5 cells (Figure 4B). CBP treatment
increased cytoplasmic and extracellular HA and increased
both cytoplasmic and nuclear ABCC2. HA and ABCC2
were found to be localized to the same cells (Figure 4B).
HA is increased following chemotherapy treatment and
predicts ovarian cancer outcome
To determine whether chemotherapy can increase HA
production in ovarian cancer patients, we measuredFigure 4 Chemotherapy treatment increases ABCC2 expression
in ovarian cancer cells. A. qRT-PCR for ABCC2 expression. Ovarian
cancer cells treated with LD50 CBP for 72 hr. OVCAR-5 cells also treated
in presence or absence of HA oligomers (HYA oligo, 250 μg/ml).
Relative gene expression was determined by calibration against no CBP
control and normalized to the house keeping gene β-actin using the
2-ΔΔCT method. Data represents mean ± SEM from 3 independent
experiments performed in triplicate. B. OVCAR-5 treated with LD50 CBP
for 72 hr. Fixed cells were incubated with biotinylated HABP
and ABCC2 mouse monoclonal antibody and visualized with Cy3-
conjugated streptavidin (red) and FITC-conjugated donkey anti-
mouse immunoglobulins (green) respectively. Nuclei are
counterstained with DAPI dye (blue).serum HA levels at diagnosis, following chemotherapy,
as well as at the time of recurrence. HA serum levels
were also compared with those of patients with benign
ovarian tumors and healthy controls. Serum HA levels
were significantly higher in patients with ovarian cancer,
when compared with normal controls (Figure 5A). HA
levels were not significantly different between patients
with ovarian cancer at diagnosis or benign ovarian tu-
mors (Figure 5A), or between different ovarian cancer
subtypes or stages of disease (Table 1). Serum HA levels
were significantly increased in patients who received at
least 2 cycles of chemotherapy (Figure 5A), and in pa-
tients at 1st or 2nd recurrence compared with serum HA
levels at time of diagnosis (Figure 5A). Paired analysis
found that serum HA levels were increased following
chemotherapy in 75% (24/32) of patients (Figure 5B).
We assessed HA levels in ovarian cancer tissues prior
to treatment (at surgery) and in ovarian cancer tissues
from patients that received neo-adjuvent chemotherapy
and at recurrence to determine if HA production in
ovarian cancer cells is increased following chemotherapy
treatment. HA intensity in the cancer associated stroma
was not different between the three tissue groups exam-
ined (P = 0.443, Pearson Chi Square). HA positive cancer
cells were observed in 67% (6/9) of cancer tissues post
chemotherapy (Figure 5D) and all recurrent cancer tissuesFigure 5 HA is increased following chemotherapy treatment.
A. HA serum levels in ovarian cancer patients at diagnosis (cancer;
n = 101), after at least 2 cycles of chemotherapy (post
chemotherapy; n = 52), and at 1st recurrence n = 17) and 2nd
recurrence (n = 5), as well as serum from patients with benign
ovarian tumors (benign; n = 22) and from healthy controls
(normal; n = 27). *, significantly different from normal control
(P < 0.05, Mann Whitney U test). **, significantly different from HA
serum level at diagnosis (P < 0.05, Mann Whitney U test). The bars
specify the median values in each group. B. Fold change in serum
HA levels in matched ovarian cancer patients at diagnosis and
following chemotherapy treatment (n = 32). *, significantly
increased from level at diagnosis (Wilcoxon rank test, P < 0.0001).
HA staining in representative ovarian cancer tissues prior to
treatment (C), post chemotherapy (D) and at recurrence (E).
Ep = cancer cells, St = peritumoral stroma. Bar = 100 μm.
Table 1 HA levels in patients serum samples
Tissue n Patient age (years) HA serum level (μg/ml)
Median (range) Median (range)
Normal ovaries 27 50 (48–58) 9.6 (0.6–114.3)
Benign ovarian tumors 22 51 (35–62) 17.3 (1–136.5)
Ovarian cancers Total 101 61 (25–90) 28.7 (0.3–1543.7)
Serous 59 61 (25–85) 26.7 (0.3–172.8)
Endometrioid 16 55 (33–90) 37.0 (4.2–1543.9)
Mucinous 7 54 (37–74) 26.2 (1.5–70.7)
Clear Cell 9 62 (37–82) 25.9 (2.2–101.9)
Others 10 60 (32–88) 25.5 (13.6–111.9)
Stage
1 31 55 (33–90) 26.0 (1.1–1543.7)
2 6 59 (44–65) 19.0 (1.5–37.0)
3 58 62 (25–88) 29.6 (0.3–172.8)
4 4 64 (61–79) 19.8 (15.8–89.3)
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serous ovarian cancer tissues obtained at surgery prior to
any treatment (0/10, Figure 5C) (P = 0.001, Pearson Chi
Square test).
Kaplan-Meier analysis, using serum HA levels separated
into quartiles demonstrated earlier relapses and deaths in
the group of patients with serum HA levels > 50 μg/ml
(fourth quartile) compared to patients in the other quartile
groups (combined 1st-3rd quartiles). The 12 month
progression-free survival rate in patients with ≤50 μg/
ml HA was 89.8% but only 45.8% in patients with
serum HA levels > 50 μg/ml (P = 0.014, Figure 6A).
Similarly the 2 year survival rate was 84% in the group
of patients with HA ≤ 50 μg/ml and only 23.7% in the
group of patients with HA > 50 μg/ml (P = 0.036,
Figure 6B). Cox regression analysis showed that pa-
tients with serum HA levels > 50 μg/ml had a 2.7 fold
(P = 0.02) increased risk of disease progression and
2.9-fold increased (P = 0.046) risk of ovarian cancer
death. Due to cohort size, multivariate analysis was not
performed in this study.
HA regulates expression of ABC transporters
We compared relative expression levels of ABC trans-
porter protein amongst the 4 ovarian cancer cell lines
using the least invasive ovarian cancer cell line, OVCAR-3,
as a calibrator (Figure 7A-D). We found highest expres-
sion of ABCC1 (4.8 fold, Figure 7B) and ABCC3 (12.4 fold,
Figure 7D) in SKOV-3 cells, shown in Figure 1A to be the
most resistant to CBP and to produce the highest level of
HA (Figure 2A). Highest levels of ABCC2 (286 fold) were
observed in OV-90 cells (Figure 7C). ABCB3 expression
was lowest in OV-90 cells (Figure 7A) whilst ABCB4
expression was only detected in OVCAR-5 cells (data notshown). We found no ABCB1 expression in any of the
ovarian cancer cell lines (data not shown). The MCF-7
breast cancer cell line, used as positive control for the
real-time PCR experiments, expressed ABCB1 (data not
shown).
To further explore the molecular mechanisms of
chemoresistance in ovarian cancer cells, we investigated
whether HA treatment could regulate the expression of
ABC transporters. HA (5 μg/ml) did not induce ABCB1
expression in any of the ovarian cancer cell lines used in
this study (data not shown). However, a significant
increase in expression of ABCB3 (1.87 fold, P = 0.004,
Figure 8A), ABCC1 (3.00 fold, P = 0.012, Figure 8C),
ABCC2 (3.18 fold, P = 0.002, Figure 8D), and ABCC3
(3.40 fold, P = 0.003, Figure 8E) was observed in
OVCAR-5 cells treated with HA (5 μg/ml) for 72 hours.
ABCB3 (1.61 fold, P = 0.028, Figure 8A), ABCC2 (1.75 fold,
P = 0.039, Figure 8C) and ABCC3 (3.08 fold, P = 0.048,
Figure 8E) expression was also significantly increased in
OV-90 cells following HA treatment. ABCB4 expression
in OVCAR-5 cells was not altered by HA treatment
(Figure 8B). No significant change in ABC transporter
expression was observed in HA treated OVCAR-3 cells
(Figure 8A-E). The addition of HA oligomers (250 μg/ml)
completely abrogated the increase in expression of ABCB3
(Figure 8A), ABCC1 (Figure 8C), ABCC2 (Figure 8D), and
partially blocked ABCC3 expression in OVCAR-5 cells
(Figure 8E). The expression of the anti-apoptotic gene
Bcl-xL was not altered by HA treatment in any of the
cell lines (Figure 8F).
Discussion
Chemotherapy resistance is one of the most challenging
problems in cancer treatment. The molecular mechanisms
Figure 6 Serum HA predicts ovarian cancer progression-free
survival and overall survival. A. Patients with high serum HA
(> 50 μg/ml, n = 15) had a significantly reduced progression-free
survival compared to patients with low serum HA (≤50 μg/mL,
n = 62), log rank statistic = 6.035, P = 0.014. B. Patients with high
serum HA (> 50 μg/ml, n = 16) had a significantly reduced overall
survival compared to patients with low serum HA (≤50 μg/mL,
n = 67), log rank statistic = 4.39, P = 0.036.
Figure 7 ATP binding cassette (ABC) transporter expression by
ovarian cancer cell lines. ABCB3 (A), ABCB4 (B), ABCC2 (C) and
ABCC3 (D). Relative gene expression was determined by calibration
against OVCAR-3 cell expression and normalized to the house
keeping gene β-actin using the 2-ΔΔCT method. Data represents
mean ± SEM from 3 independent experiments performed in
triplicate. *, significantly different from OVCAR-3 cells (P < 0.05, One
Way ANOVA & Tukey multiple comparison post hoc test).
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poorly understood. Multidrug transporter proteins, such
as ABC transporters, are well known for their contribution
to chemoresistance through the efflux of cytotoxic drugs
from cancer cells [40,41]. ABC transporter expression and
chemoresistance has been reported to be modulated by
HA-CD44 interactions [30,32-34,42]. Although the im-
portance of HA and CD44 in ovarian cancer progres-
sion has been well established [18,25,43], the knowledge
about their significance in mediating ovarian cancer
chemoresistance is limited.
Our results show that HA induces chemoresistance
against CBP, and increases the expression of the ABC
transporters, ABCB3, ABCC1, ABCC2, and ABCC3 in
ovarian cancer cell lines expressing the HA receptor,CD44. By measuring serum HA levels in ovarian cancer
patients, we demonstrate for the first time that HA
levels are elevated in patients following chemotherapy
treatment and at recurrence compared with HA levels at
diagnosis. Importantly, higher serum HA levels (> 50 μg/ml)
were associated with reduced progression-free and overall
survival. Our findings confirm that, in addition to their
important role in promoting malignant ovarian cancer cell
behaviour, CD44-HA interactions also play a significant
role in mediating chemoresistance.
HA production in ovarian cancer cells was increased
in ovarian cancer tissues from patients that received
neoadjuvent chemotherapy and at recurrence com-
pared to tissues collected at surgery prior to any treat-
ment. Other potential mechanisms that may also
contribute to the increased HA serum levels following
chemotherapy were not investigated further in this
study. Pro-inflammatory cytokines including tumour
necrosis factor and interleukin-1β shown to be in-
creased by chemotherapy treatment [44,45] and stimu-
late HA production in a variety of cell types [46-49]
may also contribute to increasing serum HA levels.
Our data supports the model that chemoresistance is
acquired by chemotherapy-induced HA production and
increases ovarian cancer cell survival which contributes
to chemoresistance by increasing the expression of ABC
transporter proteins via a HA-CD44 mediated pathway.
CBP treatment increased the secretion of HA in ovarian
cancer cell lines by increasing HA synthesis, as we found
corresponding increased Has2 and Has3 expression in
Figure 8 HA regulates expression of ATP binding cassette
(ABC) drug transporters. A. ABCB3. B. ABCC4. C. ABCC1. D. ABCC2.
E. ABCC3 & F. BCL21. Ovarian cancer cells treated with HA (5 μg/ml)
for 72 hr. OVCAR-5 cells also treated in presence or absence of HA
oligomers (HYA oligo, 250 μg/ml). Relative gene expression was
determined by calibration against no HA control and normalized to
the house keeping gene β-actin using the 2-ΔΔCT method following
72 hr HA treatment. Data represents mean ± SEM from 2–4
independent experiments performed in triplicate following.
*, significantly different from no HA control (P < 0.05, independent t
test). C = no HA (control medium), HA = hyaluronan (5 μg/ml).
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OVCAR-3 cells. In accord with our results, increased
chemotherapy resistance was observed in MCF7 breast
cancer cells overexpressing Has2 [50]. Furthermore,
chemoresistant lymphoma cell lines were also found to
have greater expression of Has1, Has2, and Has3 tran-
scripts, and to secrete higher levels of HA [51].
Our finding that HA promotes chemoresistance of
ovarian cancer cells agrees with previous studies using
other cancer cell lines showing that HA can increase the
LD50 of various chemotherapy drugs [26-29,31]. We
have found that the addition of either neutralizing CD44
antibody or HA oligomers (6–10 sugar residues), which
interact monovalently with CD44 and competitively
block polyvalent interactions between CD44 and en-
dogenous HA, blocked the HA induced chemoresistance
in CD44 positive ovarian cancer cell lines but not in the
CD44 negative, OVCAR-3 cells. These findings demon-
strate the significance of HA-CD44 interactions in thismechanism. Furthermore, HA oligomers were able to
sensitize chemoresistant SKOV-3 cells to CBP. These
findings agree with previous studies demonstrating that
HA oligomers can sensitize various carcinoma cell lines
to chemotherapy drugs, including doxorubicin, taxol,
and vincristine, both in vitro and in vivo [30,32,34].
More recently, Slomiany et al. found that HA oligomers
decreased doxorubicin resistance of malignant peripheral
nerve sheath tumours and suppressed HA secretion in
these tumors [52]. Importantly, the HA oligomers and
doxorubicin acted synergistically at suboptimal doses
and induced tumour regression to a greater extent than
either agent alone [52].
Several studies have also shown that HA-CD44 inter-
actions regulate ABC transporter expression and activity
[28,30-32]. HA has been shown to stimulate ABCB1 ex-
pression and ABCB1 activity in various cancer cell lines
[28,30-32]. HA-CD44 interactions also regulate expres-
sion of ABCG2 (BCRP) in glioma cells [34]. ABCC2
expression is upregulated in non small cell lung cancer
cells (H322) overexpressing CD44, which are more re-
sistant to cisplatin when cultured on a HA matrix [33].
Human mesenchymal stem cells cultured on a layer of
HA are more resistant to doxorubicin and produce in-
creased levels of ABCB1 [53]. Interestingly, we found
that SKOV-3 cells, which produced the highest HA
levels, were most resistant to CBP and expressed the
highest levels of ABCC1 and ABCC3. CD44 co-localizes
in the plasma membrane of cancer cells with ABCB1
and ABCG2, and HA antagonists rapidly induce intern-
alization of these transporters and CD44 to make them
ineffective [34,52,54]. These findings have led to the sug-
gestion that multivalent interactions between HA and
CD44 may be necessary for stabilization of transporter
interactions within the plasma membrane [52].
Bourguignon et al. have previously reported ABCB1 ex-
pression in SKOV-3.ipl, a variant cell line established from
mouse xenograft, to be increased by HA treatment [28].
However, we did not observe ABCB1 expression in any of
the ovarian cancer cell lines examined, neither in the ab-
sence nor presence of HA. In contrast to Bourguignon
et al. 2009 [31], we did not observe an effect on Bcl-2l
expression by HA treatment in the ovarian cancer cell
lines. In our experiments, HA alone had no effect on cell
survival and an anti-apoptotic mechanism was excluded.
Our findings suggest that HA induces chemoresistance by
inducing ABC transporter expression, which increases
ovarian cancer cell survival by increasing the efflux of CBP
from the cells.
Our data supports a role for ABCB3, ABCC1, ABCC2,
and ABCC3 in ovarian cancer chemoresistance, which is
in agreement with previous studies. Overexpression of
ABCC1 and ABCC2 in human ovarian cancer cells con-
ferred marked resistance to chemotherapeutics, such as
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ABCC1 was observed in ovarian cancers from chemo-
therapy non-responders [56]. Higher gene expression of
ABCC1 and ABCC3 was also found in ovarian cancer
patients with unfavourable outcome following debulking
surgery and platinum based chemotherapy [12]. Nuclear
membrane localization of ABCC2 has been shown to
predict resistance to cisplatin [39]. A recent study by
Auner et al. identified gene expression of the four ABC
transporters ABCC1, ABCC2, ABCC3 and ABCB3 to be
significantly elevated in recurrent ovarian cancer com-
pared to benign tumors and untreated primary cancer
[15]. Oxaliplatin resistant ovarian cancer cells have been
shown to overexpress ABCC1 and ABCC4 [57]. The
importance of ABCC2 in mediating chemoresistance is
supported by our findings showing increased expression
of ABCC2 in ovarian cancer cells following treatment
with CBP and verified by studies which showed that
ABCC2 siRNA knockdown could reverse cisplatin and
paclitaxel resistance in ovarian cancer cell lines [39,58].
HA is a promising candidate for increasing efficacy
and reducing toxicity of cancer therapies. Administra-
tion of HA-chemotherapy conjugates, which allows
chemotherapy drugs to enter cancer cells via a CD44
receptor-mediated mechanism, resulted in increased
therapeutic activity compared with chemotherapy alone
[59,60]. In the taxane resistant HeyA8-MDR ovarian
cancer xenograft model, metronomic doses (more fre-
quent lower therapeutic doses) of paclitaxel-HA conju-
gate had a more effective anti-tumor activity and
exhibited reduced toxicity compared with mice that
were administered the maximum tolerated doses of the
paclitaxel-HA conjugate [61]. More recent studies have
demonstrated that HA is a barrier for chemotherapy drugs
in pancreatic cancers [62,63]. Systemic administration of
chemotherapy together with hyaluronidase (PEGPH20),
which degrades HA, improved blood vessel perfusion and
resulted in increased sensitivity and improved survival in
pancreatic cancer mouse models [62,63]. Clinical trials are
ongoing to examine the effect of depleting HA in patients
with pancreatic cancer (NCT01959139, NCT01839487 &
NCT01453153, http://clinicaltrials.gov). Together these
studies and our recent findings support the notion that
targeting HA in the tumor microenvironment is an
important future direction for cancer therapy.
Conclusions
This study has demonstrated that HA treatment reduces
the ability of CBP to cause cell death and increases the ex-
pression of ABC transporters in CD44 positive ovarian
cancer cell lines. Importantly, we also found that serum
HA levels are increased in ovarian cancer patients follow-
ing chemotherapy treatment and at recurrence. These
findings support the theory that chemoresistance isacquired as a response to chemotherapy and the increased
production of HA can contribute to chemoresistance by
regulating expression of ABC transporters via a HA-CD44
mediated pathway. Targeting the HA-CD44 signaling
pathway is therefore a promising strategy to overcome
chemoresistance and improve ovarian cancer survival.
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